Initial public offer of 58,51,200 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Pramodini Medicare Limited ("The Company" or "Pramodini" or "The Issuer") at an offer price of Rs. 118 per equity share for cash, aggregating to Rs. 69.04 Crores comprising of fresh offer of 53,50,800 equity shares aggregating to Rs. 63.14 Crores ("Fresh Issue") and an offer for sale of 5,00,400 equity shares by Chalasani Kuldeep Kumar, Chalasani Kavitha and Sri Ram Medicare Private Limited ("Promoter Selling Shareholders") aggregating to Rs. 5.90 Crores ("Offer For Sale") ("Public Offer"). The offer includes a reservation of 3,36,000 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 118 per equity share for cash, aggregating Rs. 3.96 Crores will be reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The public offer less market maker reservation portion i.e. Net offer of 55,15,200 equity shares of face value of Rs.10/-each, at an offer price of Rs. 118 per equity share for cash, aggregating Rs. 65.08 Crores is herein after referred to as the "Net Offer". The public offer and net offer will constitute 26.54% and 25.02% respectively of the post- offer paid-up equity share capital of the company.
Price Band: Rs. 118/- per equity share of face value of Rs. 10/- each.
The floor price is 11.80 times of the face value of the equity shares.
Bids can be made for a minimum of 1,200 equity shares and in multiples of 1,200 equity shares thereafter.
IPO Details
Issue
Money Payable On
Opens On
Closes On
Application
Allotment
12-Aug-2026
14-Aug-2026
₹ 118.00
₹ 0.00
Minimum Application for shares in Nos
Minimum Application for shares in Nos : 2400.0 Further Multiples of : 1200.0
(₹)Cr.
Lead Managers to the Issue
Project Cost
55.91
Smart Horizon Capital Advisors Private Limited
Project Financed through Current Offer
69.04
Post Issue Equity Share Capital
22.05
Issue Price
₹118.00
Projects
Projects
Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres; and
General corporate purposes and unidentified inorganic acquisition